- Home
- GOCO vs NRXP Comparison
GOCO vs NRXP Comparison
Compare GOCO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- NRXP
- Stock Information
- Founded
- GOCO 2001
- NRXP 2015
- Country
- GOCO United States
- NRXP United States
- Employees
- GOCO N/A
- NRXP N/A
- Industry
- GOCO Specialty Insurers
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- GOCO Finance
- NRXP Health Care
- Exchange
- GOCO Nasdaq
- NRXP Nasdaq
- Market Cap
- GOCO 70.3M
- NRXP 73.7M
- IPO Year
- GOCO 2020
- NRXP N/A
- Fundamental
- Price
- GOCO $2.85
- NRXP $2.17
- Analyst Decision
- GOCO Hold
- NRXP Strong Buy
- Analyst Count
- GOCO 2
- NRXP 5
- Target Price
- GOCO $12.00
- NRXP $31.60
- AVG Volume (30 Days)
- GOCO 49.1K
- NRXP 469.5K
- Earning Date
- GOCO 11-13-2025
- NRXP 11-17-2025
- Dividend Yield
- GOCO N/A
- NRXP N/A
- EPS Growth
- GOCO N/A
- NRXP N/A
- EPS
- GOCO N/A
- NRXP N/A
- Revenue
- GOCO $738,338,000.00
- NRXP $242,000.00
- Revenue This Year
- GOCO $2.06
- NRXP N/A
- Revenue Next Year
- GOCO $5.47
- NRXP $395.09
- P/E Ratio
- GOCO N/A
- NRXP N/A
- Revenue Growth
- GOCO 7.56
- NRXP N/A
- 52 Week Low
- GOCO $2.17
- NRXP $1.15
- 52 Week High
- GOCO $21.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- GOCO 39.33
- NRXP 36.74
- Support Level
- GOCO $2.24
- NRXP $1.99
- Resistance Level
- GOCO $3.52
- NRXP $2.81
- Average True Range (ATR)
- GOCO 0.25
- NRXP 0.20
- MACD
- GOCO 0.01
- NRXP -0.03
- Stochastic Oscillator
- GOCO 50.33
- NRXP 21.95
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.